M&A talk prompts Actelion to weigh options

With rumors of a buyout swirling, Actelion has formed a special board committee to look at "strategic alternatives" for the company, including a potential sale, sources tell the Wall Street Journal. The committee has already hired a financial adviser, and it's going to open its doors for talks with interested buyers.

WSJ's sources cite Bristol-Myers Squibb--a potential deal that spawned furious speculation yesterday--as well as Roche, GlaxoSmithKline and Amgen. Kepler Capital Markets analyst Tero Weckroth wrote in a note that Bayer would be a good match with Actelion, but sources close to the German drugmaker tell Reuters that Bayer's not interested.

The company's chosen future may not end up including a sale, however. As WSJ points out, Actelion CEO Jean-Paul Clozel has said he would prefer the company remain independent. "It makes sense that they evaluate their options," Raymond James analyst Eric Le Berrigaud tells Bloomberg. "It may not necessarily mean a sale. It could mean, for example, a strong shareholder coming in."

- see the WSJ news
- get more from Bloomberg 
- read the Reuters story

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.